Key Insights
The global Arthritis Therapeutics market is projected to reach $19.55 billion by 2025, with a compound annual growth rate (CAGR) of 4.6% through 2033. This expansion is driven by the rising global prevalence of arthritis, attributed to an aging population, increasing obesity rates, and enhanced understanding of inflammatory and autoimmune conditions. Key growth catalysts include advancements in drug discovery and development, yielding more targeted and effective treatments such as biologic agents and DMARDs. The market is further stimulated by the shift towards personalized medicine and a growing demand for minimally invasive treatment options. Enhanced healthcare expenditure and improved access to advanced diagnostics and treatments in emerging economies are also expected to accelerate market penetration. The industry is witnessing a significant trend in the development of novel biologic therapies and combination treatments designed to address complex arthritic conditions, offering improved patient outcomes and disease management.
Arthritis Therapeutics Industry Market Size (In Billion)
Market segmentation highlights a diverse therapeutic landscape. While Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) and Disease-Modifying Antirheumatic Drugs (DMARDs) currently hold substantial shares, the Biologic Agents segment is anticipated to experience the fastest growth. This is due to their targeted mechanisms of action and increasing clinical efficacy in managing severe arthritis forms like rheumatoid arthritis and psoriatic arthritis. Oral administration remains the primary route, though parenteral formulations, especially for biologics, are gaining traction for their bioavailability and efficacy. Despite market innovation and unmet medical needs, restraints may include the high cost of novel therapies, potential side effects, and regulatory approval challenges. However, the strategic investments and R&D efforts by major pharmaceutical players are expected to overcome these obstacles and sustain the upward trajectory of the Arthritis Therapeutics market. North America and Europe currently lead, with the Asia Pacific region exhibiting the most promising growth potential in the forecast period.
Arthritis Therapeutics Industry Company Market Share
This comprehensive report provides a dynamic, SEO-optimized analysis of the global Arthritis Therapeutics industry. Leveraging high-volume keywords, it offers actionable intelligence for stakeholders, covering historical trends from 2019–2024 and projecting through 2033. With a base year of 2025, this report delivers unparalleled insights into market structure, trends, dominant segments, product innovations, key drivers, challenges, and the competitive landscape.
Arthritis Therapeutics Industry Market Structure & Competitive Landscape
The Arthritis Therapeutics Industry is characterized by a moderately concentrated market structure, driven by significant R&D investments and a robust pipeline of innovative therapies. Key innovation drivers include the increasing prevalence of autoimmune diseases, advancements in biologic drug development, and the growing understanding of disease pathophysiology. Regulatory impacts, particularly stringent approval processes by agencies like the USFDA and EMA, significantly shape market entry and product lifecycle management. Product substitutes, primarily generics and biosimil versions of established treatments, exert pressure on pricing and market share for originator products. End-user segmentation highlights a growing demand for targeted therapies, leading to specialized treatment approaches. Mergers and Acquisitions (M&A) trends indicate strategic consolidation, with major players acquiring promising early-stage assets and smaller biotech firms to expand their portfolios and market reach. The market is actively shaped by companies such as UCB Biosciences Inc, Otsuka Pharmaceutical, Celgene Corporation (Bristol-Myers Squibb), Eisai Inc, AbbVie Inc, Sumitomo Dainippon Pharma Co, Johnson & Johnson, Sanofi S A, and Pfizer Inc. While precise concentration ratios are dynamic, recent M&A activities point towards strategic alignments, aiming to capture a larger share of the multi-billion dollar arthritis therapeutics market.
Arthritis Therapeutics Industry Market Trends & Opportunities
The Arthritis Therapeutics Industry is experiencing robust growth, projected to reach billions in market valuation by 2033. This expansion is fueled by a confluence of factors, including the rising global incidence of arthritis and related inflammatory conditions, an aging population prone to degenerative joint diseases, and increasing healthcare expenditure. Technological shifts are profoundly impacting the market, with a discernible move towards precision medicine and the development of targeted therapies. Biologics, particularly monoclonal antibodies and JAK inhibitors, are at the forefront of this innovation, offering improved efficacy and safety profiles compared to traditional treatments. Consumer preferences are increasingly leaning towards minimally invasive treatments with reduced side effects, driving demand for novel oral formulations and advanced parenteral delivery systems. The competitive landscape is intensifying, with established pharmaceutical giants and agile biotechnology firms vying for market dominance through extensive R&D, strategic partnerships, and aggressive commercialization strategies. The market is witnessing significant CAGR growth, estimated at XX%, driven by unmet medical needs and the continuous influx of novel therapeutic agents. Market penetration rates for advanced biologic therapies are steadily increasing across developed and emerging economies.
Dominant Markets & Segments in Arthritis Therapeutics Industry
The Biologic Agents segment is currently dominating the Arthritis Therapeutics Industry, owing to their targeted action and superior efficacy in managing complex inflammatory conditions like rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Within drug classes, Disease-Modifying Antirheumatic Drugs (DMARDs), both conventional synthetic (csDMARDs) and biologic (bDMARDs), hold a substantial market share, with bDMARDs experiencing particularly strong growth.
- Leading Region: North America, driven by high healthcare spending, advanced research infrastructure, and early adoption of innovative therapies, commands a significant market share. The United States, in particular, is a leading country, propelled by robust pharmaceutical R&D and a large patient population.
- Dominant Drug Class: Biologic Agents, including TNF inhibitors, IL-17 inhibitors, and JAK inhibitors, are pivotal. For instance, the approval and expanded use of IL-17 inhibitors for psoriatic arthritis showcase their market impact.
- Route of Administration: While Oral administration remains convenient and widely used for NSAIDs and some DMARDs, the Parenteral route is critical for the efficacy of most biologic agents, driving significant market revenue. Innovations in subcutaneous and intravenous formulations continue to shape this segment.
- Key Growth Drivers (Biologics):
- Increased understanding of the inflammatory pathways involved in various arthritis forms.
- Development of highly specific biologics with improved safety profiles.
- Growing preference for targeted therapies over broad immunosuppression.
- Positive clinical trial outcomes demonstrating long-term disease control and remission.
- Key Growth Drivers (DMARDs):
- Cost-effectiveness of csDMARDs in initial treatment regimens.
- Continued research into novel synthetic pathways for DMARDs.
- Integration of DMARDs in combination therapies with biologics for enhanced efficacy.
The market for Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), while mature, continues to be a significant segment due to their widespread use for pain and inflammation management, particularly for osteoarthritis. However, their growth is tempered by concerns regarding long-term side effects. Immunosuppressants, though crucial for certain autoimmune arthropathies, represent a smaller segment compared to biologics and advanced DMARDs. The "Other Drug Classes" segment encompasses emerging therapies and novel mechanisms of action, holding potential for future market disruption.
Arthritis Therapeutics Industry Product Analysis
Product innovation in the Arthritis Therapeutics Industry is heavily focused on developing targeted therapies with improved efficacy and reduced side effect profiles. Key advancements include next-generation biologic agents that selectively inhibit specific inflammatory cytokines (e.g., IL-17, IL-23) and novel small molecules like tyrosine kinase 2 (TYK2) inhibitors. These innovations offer enhanced patient outcomes by achieving higher remission rates and improving quality of life. Competitive advantages stem from superior clinical efficacy, convenient administration routes (e.g., oral formulations for systemic therapies), and favorable safety profiles, enabling broader patient access and long-term treatment adherence.
Key Drivers, Barriers & Challenges in Arthritis Therapeutics Industry
Key Drivers: The Arthritis Therapeutics Industry is propelled by several critical factors. Technologically, breakthroughs in understanding disease mechanisms are leading to the development of highly targeted therapies, such as biologics and novel small molecules. Economically, increasing global healthcare expenditure and a rising prevalence of arthritis, particularly among aging populations, create a substantial market demand. Policy-driven factors, including government initiatives to improve access to advanced treatments and favorable reimbursement policies for innovative drugs, further catalyze growth. The continuous pipeline of novel drug candidates in clinical trials promises future market expansion.
Barriers & Challenges: Despite strong growth prospects, the industry faces significant hurdles. Regulatory complexities, including lengthy and expensive approval processes for new drug entities, pose a substantial barrier. Supply chain issues, especially for complex biologic manufacturing and distribution, can impact product availability and cost. Intense competitive pressures from both originator companies and the growing biosimilar market necessitate continuous innovation and strategic market positioning. High R&D costs and the risk of clinical trial failures also present considerable financial challenges.
Growth Drivers in the Arthritis Therapeutics Industry Market
The Arthritis Therapeutics Industry is experiencing significant growth driven by several key factors. Technologically, the continuous discovery of novel biological targets and the development of precision medicine approaches are leading to more effective and safer treatments. Economically, rising global healthcare spending and an increasing patient population suffering from various forms of arthritis are expanding market opportunities. Regulatory advancements, coupled with supportive government policies aimed at improving access to advanced therapies, further fuel this growth. The unmet need for disease-modifying treatments for severe inflammatory arthritis remains a powerful catalyst for ongoing innovation and market penetration.
Challenges Impacting Arthritis Therapeutics Industry Growth
Several challenges are impacting the growth trajectory of the Arthritis Therapeutics Industry. Regulatory hurdles, characterized by stringent approval pathways and post-market surveillance requirements, can delay market entry and increase development costs. Supply chain complexities associated with biologic manufacturing and cold chain logistics present significant operational challenges, potentially affecting product availability and affordability. Intense competitive pressures from established players, generic manufacturers, and the burgeoning biosimilar market necessitate continuous innovation and aggressive commercial strategies to maintain market share and profitability. Furthermore, pricing pressures and reimbursement challenges in various healthcare systems can impact market access for novel and expensive therapeutic options.
Key Players Shaping the Arthritis Therapeutics Industry Market
- UCB Biosciences Inc
- Otsuka Pharmaceutical
- Celgene Corporation (Bristol-Myers Squibb)
- Eisai Inc
- AbbVie Inc
- Sumitomo Dainippon Pharma Co
- Johnson & Johnson
- Sanofi S A
- Pfizer Inc
Significant Arthritis Therapeutics Industry Industry Milestones
- September 2022: Significant long-term data from the KEEPsAKE trials demonstrated that over 50% of adult psoriatic arthritis patients treated with Skyrizi (risankizumab, 150mg) achieved a 90% reduction in the Psoriasis Area and Severity Index (PASI 90) and an American College of Rheumatology 20 (ACR20) response at 100 weeks. These results indicate the effectiveness of Skyrizi in treating psoriatic arthritis, reinforcing its market position.
- September 2022: The United States Food and Drug Administration (USFDA) granted approval to Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. This approval represents a significant milestone for the psoriatic arthritis therapeutics market, as Deucravacitinib has the potential to become a new option for patients suffering from this condition, introducing a novel mechanism of action.
Future Outlook for Arthritis Therapeutics Industry Market
The future outlook for the Arthritis Therapeutics Industry remains exceptionally strong, driven by ongoing advancements in understanding disease pathogenesis and the development of innovative treatment modalities. Key growth catalysts include the expanding pipeline of biologics targeting novel inflammatory pathways, the increasing adoption of precision medicine for personalized treatment strategies, and the growing demand for oral therapies that offer greater patient convenience. Strategic opportunities lie in emerging markets with a rising incidence of inflammatory diseases and unmet medical needs. Market potential is further amplified by the persistent demographic trends of an aging global population and the continuous drive for improved patient outcomes and quality of life.
Arthritis Therapeutics Industry Segmentation
-
1. Drug Class
- 1.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
- 1.2. Disease-Modifying Antirheumatic Drugs (DMARDs)
- 1.3. Immunosuppressants
- 1.4. Biologic Agents
- 1.5. Other Drug Classes
-
2. Route of Administration
- 2.1. Oral
- 2.2. Parenteral
- 2.3. Other Routes of Administration
Arthritis Therapeutics Industry Segmentation By Geography
-
1. North America
- 1.1. United States
- 1.2. Canada
- 1.3. Mexico
-
2. Europe
- 2.1. Germany
- 2.2. United Kingdom
- 2.3. France
- 2.4. Italy
- 2.5. Spain
- 2.6. Rest of Europe
-
3. Asia Pacific
- 3.1. China
- 3.2. Japan
- 3.3. India
- 3.4. Australia
- 3.5. South Korea
- 3.6. Rest of Asia Pacific
-
4. Middle East and Africa
- 4.1. GCC
- 4.2. South Africa
- 4.3. Rest of Middle East and Africa
-
5. South America
- 5.1. Brazil
- 5.2. Argentina
- 5.3. Rest of South America
Arthritis Therapeutics Industry Regional Market Share
Geographic Coverage of Arthritis Therapeutics Industry
Arthritis Therapeutics Industry REPORT HIGHLIGHTS
| Aspects | Details |
|---|---|
| Study Period | 2020-2034 |
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026-2034 |
| Historical Period | 2020-2025 |
| Growth Rate | CAGR of 4.6% from 2020-2034 |
| Segmentation |
|
Table of Contents
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 2.1. Introduction
- 3. Market Dynamics
- 3.1. Introduction
- 3.2. Market Drivers
- 3.2.1. Increasing Prevalence of Psoriatic Arthritis Associated with Increasing Obesity; Strong Product Pipeline
- 3.3. Market Restrains
- 3.3.1. High Cost of Treatment
- 3.4. Market Trends
- 3.4.1. Immunosuppressants Segment is Expected to Hold a Large Share in the Market
- 4. Market Factor Analysis
- 4.1. Porters Five Forces
- 4.2. Supply/Value Chain
- 4.3. PESTEL analysis
- 4.4. Market Entropy
- 4.5. Patent/Trademark Analysis
- 5. Global Arthritis Therapeutics Industry Analysis, Insights and Forecast, 2020-2032
- 5.1. Market Analysis, Insights and Forecast - by Drug Class
- 5.1.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
- 5.1.2. Disease-Modifying Antirheumatic Drugs (DMARDs)
- 5.1.3. Immunosuppressants
- 5.1.4. Biologic Agents
- 5.1.5. Other Drug Classes
- 5.2. Market Analysis, Insights and Forecast - by Route of Administration
- 5.2.1. Oral
- 5.2.2. Parenteral
- 5.2.3. Other Routes of Administration
- 5.3. Market Analysis, Insights and Forecast - by Region
- 5.3.1. North America
- 5.3.2. Europe
- 5.3.3. Asia Pacific
- 5.3.4. Middle East and Africa
- 5.3.5. South America
- 5.1. Market Analysis, Insights and Forecast - by Drug Class
- 6. North America Arthritis Therapeutics Industry Analysis, Insights and Forecast, 2020-2032
- 6.1. Market Analysis, Insights and Forecast - by Drug Class
- 6.1.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
- 6.1.2. Disease-Modifying Antirheumatic Drugs (DMARDs)
- 6.1.3. Immunosuppressants
- 6.1.4. Biologic Agents
- 6.1.5. Other Drug Classes
- 6.2. Market Analysis, Insights and Forecast - by Route of Administration
- 6.2.1. Oral
- 6.2.2. Parenteral
- 6.2.3. Other Routes of Administration
- 6.1. Market Analysis, Insights and Forecast - by Drug Class
- 7. Europe Arthritis Therapeutics Industry Analysis, Insights and Forecast, 2020-2032
- 7.1. Market Analysis, Insights and Forecast - by Drug Class
- 7.1.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
- 7.1.2. Disease-Modifying Antirheumatic Drugs (DMARDs)
- 7.1.3. Immunosuppressants
- 7.1.4. Biologic Agents
- 7.1.5. Other Drug Classes
- 7.2. Market Analysis, Insights and Forecast - by Route of Administration
- 7.2.1. Oral
- 7.2.2. Parenteral
- 7.2.3. Other Routes of Administration
- 7.1. Market Analysis, Insights and Forecast - by Drug Class
- 8. Asia Pacific Arthritis Therapeutics Industry Analysis, Insights and Forecast, 2020-2032
- 8.1. Market Analysis, Insights and Forecast - by Drug Class
- 8.1.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
- 8.1.2. Disease-Modifying Antirheumatic Drugs (DMARDs)
- 8.1.3. Immunosuppressants
- 8.1.4. Biologic Agents
- 8.1.5. Other Drug Classes
- 8.2. Market Analysis, Insights and Forecast - by Route of Administration
- 8.2.1. Oral
- 8.2.2. Parenteral
- 8.2.3. Other Routes of Administration
- 8.1. Market Analysis, Insights and Forecast - by Drug Class
- 9. Middle East and Africa Arthritis Therapeutics Industry Analysis, Insights and Forecast, 2020-2032
- 9.1. Market Analysis, Insights and Forecast - by Drug Class
- 9.1.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
- 9.1.2. Disease-Modifying Antirheumatic Drugs (DMARDs)
- 9.1.3. Immunosuppressants
- 9.1.4. Biologic Agents
- 9.1.5. Other Drug Classes
- 9.2. Market Analysis, Insights and Forecast - by Route of Administration
- 9.2.1. Oral
- 9.2.2. Parenteral
- 9.2.3. Other Routes of Administration
- 9.1. Market Analysis, Insights and Forecast - by Drug Class
- 10. South America Arthritis Therapeutics Industry Analysis, Insights and Forecast, 2020-2032
- 10.1. Market Analysis, Insights and Forecast - by Drug Class
- 10.1.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
- 10.1.2. Disease-Modifying Antirheumatic Drugs (DMARDs)
- 10.1.3. Immunosuppressants
- 10.1.4. Biologic Agents
- 10.1.5. Other Drug Classes
- 10.2. Market Analysis, Insights and Forecast - by Route of Administration
- 10.2.1. Oral
- 10.2.2. Parenteral
- 10.2.3. Other Routes of Administration
- 10.1. Market Analysis, Insights and Forecast - by Drug Class
- 11. Competitive Analysis
- 11.1. Global Market Share Analysis 2025
- 11.2. Company Profiles
- 11.2.1 UCB Biosciences Inc
- 11.2.1.1. Overview
- 11.2.1.2. Products
- 11.2.1.3. SWOT Analysis
- 11.2.1.4. Recent Developments
- 11.2.1.5. Financials (Based on Availability)
- 11.2.2 Otsuka Pharmaceutical
- 11.2.2.1. Overview
- 11.2.2.2. Products
- 11.2.2.3. SWOT Analysis
- 11.2.2.4. Recent Developments
- 11.2.2.5. Financials (Based on Availability)
- 11.2.3 Celgene Corporation (Bristol-Myers Squibb)
- 11.2.3.1. Overview
- 11.2.3.2. Products
- 11.2.3.3. SWOT Analysis
- 11.2.3.4. Recent Developments
- 11.2.3.5. Financials (Based on Availability)
- 11.2.4 Eisai Inc
- 11.2.4.1. Overview
- 11.2.4.2. Products
- 11.2.4.3. SWOT Analysis
- 11.2.4.4. Recent Developments
- 11.2.4.5. Financials (Based on Availability)
- 11.2.5 AbbVie Inc
- 11.2.5.1. Overview
- 11.2.5.2. Products
- 11.2.5.3. SWOT Analysis
- 11.2.5.4. Recent Developments
- 11.2.5.5. Financials (Based on Availability)
- 11.2.6 Sumitomo Dainippon Pharma Co
- 11.2.6.1. Overview
- 11.2.6.2. Products
- 11.2.6.3. SWOT Analysis
- 11.2.6.4. Recent Developments
- 11.2.6.5. Financials (Based on Availability)
- 11.2.7 Johnson & Johnson
- 11.2.7.1. Overview
- 11.2.7.2. Products
- 11.2.7.3. SWOT Analysis
- 11.2.7.4. Recent Developments
- 11.2.7.5. Financials (Based on Availability)
- 11.2.8 Sanofi S A
- 11.2.8.1. Overview
- 11.2.8.2. Products
- 11.2.8.3. SWOT Analysis
- 11.2.8.4. Recent Developments
- 11.2.8.5. Financials (Based on Availability)
- 11.2.9 Pfizer Inc
- 11.2.9.1. Overview
- 11.2.9.2. Products
- 11.2.9.3. SWOT Analysis
- 11.2.9.4. Recent Developments
- 11.2.9.5. Financials (Based on Availability)
- 11.2.1 UCB Biosciences Inc
List of Figures
- Figure 1: Global Arthritis Therapeutics Industry Revenue Breakdown (billion, %) by Region 2025 & 2033
- Figure 2: Global Arthritis Therapeutics Industry Volume Breakdown (K Unit, %) by Region 2025 & 2033
- Figure 3: North America Arthritis Therapeutics Industry Revenue (billion), by Drug Class 2025 & 2033
- Figure 4: North America Arthritis Therapeutics Industry Volume (K Unit), by Drug Class 2025 & 2033
- Figure 5: North America Arthritis Therapeutics Industry Revenue Share (%), by Drug Class 2025 & 2033
- Figure 6: North America Arthritis Therapeutics Industry Volume Share (%), by Drug Class 2025 & 2033
- Figure 7: North America Arthritis Therapeutics Industry Revenue (billion), by Route of Administration 2025 & 2033
- Figure 8: North America Arthritis Therapeutics Industry Volume (K Unit), by Route of Administration 2025 & 2033
- Figure 9: North America Arthritis Therapeutics Industry Revenue Share (%), by Route of Administration 2025 & 2033
- Figure 10: North America Arthritis Therapeutics Industry Volume Share (%), by Route of Administration 2025 & 2033
- Figure 11: North America Arthritis Therapeutics Industry Revenue (billion), by Country 2025 & 2033
- Figure 12: North America Arthritis Therapeutics Industry Volume (K Unit), by Country 2025 & 2033
- Figure 13: North America Arthritis Therapeutics Industry Revenue Share (%), by Country 2025 & 2033
- Figure 14: North America Arthritis Therapeutics Industry Volume Share (%), by Country 2025 & 2033
- Figure 15: Europe Arthritis Therapeutics Industry Revenue (billion), by Drug Class 2025 & 2033
- Figure 16: Europe Arthritis Therapeutics Industry Volume (K Unit), by Drug Class 2025 & 2033
- Figure 17: Europe Arthritis Therapeutics Industry Revenue Share (%), by Drug Class 2025 & 2033
- Figure 18: Europe Arthritis Therapeutics Industry Volume Share (%), by Drug Class 2025 & 2033
- Figure 19: Europe Arthritis Therapeutics Industry Revenue (billion), by Route of Administration 2025 & 2033
- Figure 20: Europe Arthritis Therapeutics Industry Volume (K Unit), by Route of Administration 2025 & 2033
- Figure 21: Europe Arthritis Therapeutics Industry Revenue Share (%), by Route of Administration 2025 & 2033
- Figure 22: Europe Arthritis Therapeutics Industry Volume Share (%), by Route of Administration 2025 & 2033
- Figure 23: Europe Arthritis Therapeutics Industry Revenue (billion), by Country 2025 & 2033
- Figure 24: Europe Arthritis Therapeutics Industry Volume (K Unit), by Country 2025 & 2033
- Figure 25: Europe Arthritis Therapeutics Industry Revenue Share (%), by Country 2025 & 2033
- Figure 26: Europe Arthritis Therapeutics Industry Volume Share (%), by Country 2025 & 2033
- Figure 27: Asia Pacific Arthritis Therapeutics Industry Revenue (billion), by Drug Class 2025 & 2033
- Figure 28: Asia Pacific Arthritis Therapeutics Industry Volume (K Unit), by Drug Class 2025 & 2033
- Figure 29: Asia Pacific Arthritis Therapeutics Industry Revenue Share (%), by Drug Class 2025 & 2033
- Figure 30: Asia Pacific Arthritis Therapeutics Industry Volume Share (%), by Drug Class 2025 & 2033
- Figure 31: Asia Pacific Arthritis Therapeutics Industry Revenue (billion), by Route of Administration 2025 & 2033
- Figure 32: Asia Pacific Arthritis Therapeutics Industry Volume (K Unit), by Route of Administration 2025 & 2033
- Figure 33: Asia Pacific Arthritis Therapeutics Industry Revenue Share (%), by Route of Administration 2025 & 2033
- Figure 34: Asia Pacific Arthritis Therapeutics Industry Volume Share (%), by Route of Administration 2025 & 2033
- Figure 35: Asia Pacific Arthritis Therapeutics Industry Revenue (billion), by Country 2025 & 2033
- Figure 36: Asia Pacific Arthritis Therapeutics Industry Volume (K Unit), by Country 2025 & 2033
- Figure 37: Asia Pacific Arthritis Therapeutics Industry Revenue Share (%), by Country 2025 & 2033
- Figure 38: Asia Pacific Arthritis Therapeutics Industry Volume Share (%), by Country 2025 & 2033
- Figure 39: Middle East and Africa Arthritis Therapeutics Industry Revenue (billion), by Drug Class 2025 & 2033
- Figure 40: Middle East and Africa Arthritis Therapeutics Industry Volume (K Unit), by Drug Class 2025 & 2033
- Figure 41: Middle East and Africa Arthritis Therapeutics Industry Revenue Share (%), by Drug Class 2025 & 2033
- Figure 42: Middle East and Africa Arthritis Therapeutics Industry Volume Share (%), by Drug Class 2025 & 2033
- Figure 43: Middle East and Africa Arthritis Therapeutics Industry Revenue (billion), by Route of Administration 2025 & 2033
- Figure 44: Middle East and Africa Arthritis Therapeutics Industry Volume (K Unit), by Route of Administration 2025 & 2033
- Figure 45: Middle East and Africa Arthritis Therapeutics Industry Revenue Share (%), by Route of Administration 2025 & 2033
- Figure 46: Middle East and Africa Arthritis Therapeutics Industry Volume Share (%), by Route of Administration 2025 & 2033
- Figure 47: Middle East and Africa Arthritis Therapeutics Industry Revenue (billion), by Country 2025 & 2033
- Figure 48: Middle East and Africa Arthritis Therapeutics Industry Volume (K Unit), by Country 2025 & 2033
- Figure 49: Middle East and Africa Arthritis Therapeutics Industry Revenue Share (%), by Country 2025 & 2033
- Figure 50: Middle East and Africa Arthritis Therapeutics Industry Volume Share (%), by Country 2025 & 2033
- Figure 51: South America Arthritis Therapeutics Industry Revenue (billion), by Drug Class 2025 & 2033
- Figure 52: South America Arthritis Therapeutics Industry Volume (K Unit), by Drug Class 2025 & 2033
- Figure 53: South America Arthritis Therapeutics Industry Revenue Share (%), by Drug Class 2025 & 2033
- Figure 54: South America Arthritis Therapeutics Industry Volume Share (%), by Drug Class 2025 & 2033
- Figure 55: South America Arthritis Therapeutics Industry Revenue (billion), by Route of Administration 2025 & 2033
- Figure 56: South America Arthritis Therapeutics Industry Volume (K Unit), by Route of Administration 2025 & 2033
- Figure 57: South America Arthritis Therapeutics Industry Revenue Share (%), by Route of Administration 2025 & 2033
- Figure 58: South America Arthritis Therapeutics Industry Volume Share (%), by Route of Administration 2025 & 2033
- Figure 59: South America Arthritis Therapeutics Industry Revenue (billion), by Country 2025 & 2033
- Figure 60: South America Arthritis Therapeutics Industry Volume (K Unit), by Country 2025 & 2033
- Figure 61: South America Arthritis Therapeutics Industry Revenue Share (%), by Country 2025 & 2033
- Figure 62: South America Arthritis Therapeutics Industry Volume Share (%), by Country 2025 & 2033
List of Tables
- Table 1: Global Arthritis Therapeutics Industry Revenue billion Forecast, by Drug Class 2020 & 2033
- Table 2: Global Arthritis Therapeutics Industry Volume K Unit Forecast, by Drug Class 2020 & 2033
- Table 3: Global Arthritis Therapeutics Industry Revenue billion Forecast, by Route of Administration 2020 & 2033
- Table 4: Global Arthritis Therapeutics Industry Volume K Unit Forecast, by Route of Administration 2020 & 2033
- Table 5: Global Arthritis Therapeutics Industry Revenue billion Forecast, by Region 2020 & 2033
- Table 6: Global Arthritis Therapeutics Industry Volume K Unit Forecast, by Region 2020 & 2033
- Table 7: Global Arthritis Therapeutics Industry Revenue billion Forecast, by Drug Class 2020 & 2033
- Table 8: Global Arthritis Therapeutics Industry Volume K Unit Forecast, by Drug Class 2020 & 2033
- Table 9: Global Arthritis Therapeutics Industry Revenue billion Forecast, by Route of Administration 2020 & 2033
- Table 10: Global Arthritis Therapeutics Industry Volume K Unit Forecast, by Route of Administration 2020 & 2033
- Table 11: Global Arthritis Therapeutics Industry Revenue billion Forecast, by Country 2020 & 2033
- Table 12: Global Arthritis Therapeutics Industry Volume K Unit Forecast, by Country 2020 & 2033
- Table 13: United States Arthritis Therapeutics Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 14: United States Arthritis Therapeutics Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 15: Canada Arthritis Therapeutics Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 16: Canada Arthritis Therapeutics Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 17: Mexico Arthritis Therapeutics Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 18: Mexico Arthritis Therapeutics Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 19: Global Arthritis Therapeutics Industry Revenue billion Forecast, by Drug Class 2020 & 2033
- Table 20: Global Arthritis Therapeutics Industry Volume K Unit Forecast, by Drug Class 2020 & 2033
- Table 21: Global Arthritis Therapeutics Industry Revenue billion Forecast, by Route of Administration 2020 & 2033
- Table 22: Global Arthritis Therapeutics Industry Volume K Unit Forecast, by Route of Administration 2020 & 2033
- Table 23: Global Arthritis Therapeutics Industry Revenue billion Forecast, by Country 2020 & 2033
- Table 24: Global Arthritis Therapeutics Industry Volume K Unit Forecast, by Country 2020 & 2033
- Table 25: Germany Arthritis Therapeutics Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 26: Germany Arthritis Therapeutics Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 27: United Kingdom Arthritis Therapeutics Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 28: United Kingdom Arthritis Therapeutics Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 29: France Arthritis Therapeutics Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 30: France Arthritis Therapeutics Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 31: Italy Arthritis Therapeutics Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 32: Italy Arthritis Therapeutics Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 33: Spain Arthritis Therapeutics Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 34: Spain Arthritis Therapeutics Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 35: Rest of Europe Arthritis Therapeutics Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 36: Rest of Europe Arthritis Therapeutics Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 37: Global Arthritis Therapeutics Industry Revenue billion Forecast, by Drug Class 2020 & 2033
- Table 38: Global Arthritis Therapeutics Industry Volume K Unit Forecast, by Drug Class 2020 & 2033
- Table 39: Global Arthritis Therapeutics Industry Revenue billion Forecast, by Route of Administration 2020 & 2033
- Table 40: Global Arthritis Therapeutics Industry Volume K Unit Forecast, by Route of Administration 2020 & 2033
- Table 41: Global Arthritis Therapeutics Industry Revenue billion Forecast, by Country 2020 & 2033
- Table 42: Global Arthritis Therapeutics Industry Volume K Unit Forecast, by Country 2020 & 2033
- Table 43: China Arthritis Therapeutics Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 44: China Arthritis Therapeutics Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 45: Japan Arthritis Therapeutics Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 46: Japan Arthritis Therapeutics Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 47: India Arthritis Therapeutics Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 48: India Arthritis Therapeutics Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 49: Australia Arthritis Therapeutics Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 50: Australia Arthritis Therapeutics Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 51: South Korea Arthritis Therapeutics Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 52: South Korea Arthritis Therapeutics Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 53: Rest of Asia Pacific Arthritis Therapeutics Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 54: Rest of Asia Pacific Arthritis Therapeutics Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 55: Global Arthritis Therapeutics Industry Revenue billion Forecast, by Drug Class 2020 & 2033
- Table 56: Global Arthritis Therapeutics Industry Volume K Unit Forecast, by Drug Class 2020 & 2033
- Table 57: Global Arthritis Therapeutics Industry Revenue billion Forecast, by Route of Administration 2020 & 2033
- Table 58: Global Arthritis Therapeutics Industry Volume K Unit Forecast, by Route of Administration 2020 & 2033
- Table 59: Global Arthritis Therapeutics Industry Revenue billion Forecast, by Country 2020 & 2033
- Table 60: Global Arthritis Therapeutics Industry Volume K Unit Forecast, by Country 2020 & 2033
- Table 61: GCC Arthritis Therapeutics Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 62: GCC Arthritis Therapeutics Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 63: South Africa Arthritis Therapeutics Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 64: South Africa Arthritis Therapeutics Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 65: Rest of Middle East and Africa Arthritis Therapeutics Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 66: Rest of Middle East and Africa Arthritis Therapeutics Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 67: Global Arthritis Therapeutics Industry Revenue billion Forecast, by Drug Class 2020 & 2033
- Table 68: Global Arthritis Therapeutics Industry Volume K Unit Forecast, by Drug Class 2020 & 2033
- Table 69: Global Arthritis Therapeutics Industry Revenue billion Forecast, by Route of Administration 2020 & 2033
- Table 70: Global Arthritis Therapeutics Industry Volume K Unit Forecast, by Route of Administration 2020 & 2033
- Table 71: Global Arthritis Therapeutics Industry Revenue billion Forecast, by Country 2020 & 2033
- Table 72: Global Arthritis Therapeutics Industry Volume K Unit Forecast, by Country 2020 & 2033
- Table 73: Brazil Arthritis Therapeutics Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 74: Brazil Arthritis Therapeutics Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 75: Argentina Arthritis Therapeutics Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 76: Argentina Arthritis Therapeutics Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 77: Rest of South America Arthritis Therapeutics Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 78: Rest of South America Arthritis Therapeutics Industry Volume (K Unit) Forecast, by Application 2020 & 2033
Frequently Asked Questions
1. What is the projected Compound Annual Growth Rate (CAGR) of the Arthritis Therapeutics Industry?
The projected CAGR is approximately 4.6%.
2. Which companies are prominent players in the Arthritis Therapeutics Industry?
Key companies in the market include UCB Biosciences Inc, Otsuka Pharmaceutical, Celgene Corporation (Bristol-Myers Squibb), Eisai Inc, AbbVie Inc , Sumitomo Dainippon Pharma Co, Johnson & Johnson, Sanofi S A, Pfizer Inc.
3. What are the main segments of the Arthritis Therapeutics Industry?
The market segments include Drug Class, Route of Administration.
4. Can you provide details about the market size?
The market size is estimated to be USD 19.55 billion as of 2022.
5. What are some drivers contributing to market growth?
Increasing Prevalence of Psoriatic Arthritis Associated with Increasing Obesity; Strong Product Pipeline.
6. What are the notable trends driving market growth?
Immunosuppressants Segment is Expected to Hold a Large Share in the Market.
7. Are there any restraints impacting market growth?
High Cost of Treatment.
8. Can you provide examples of recent developments in the market?
September 2022: Significant long-term data from the KEEPsAKE trials demonstrated that over 50% of adult psoriatic arthritis patients treated with Skyrizi (risankizumab, 150mg) achieved a 90% reduction in the Psoriasis Area and Severity Index (PASI 90) and an American College of Rheumatology 20 (ACR20) response at 100 weeks. These results indicate the effectiveness of Skyrizi in treating psoriatic arthritis.
9. What pricing options are available for accessing the report?
Pricing options include single-user, multi-user, and enterprise licenses priced at USD 4750, USD 5250, and USD 8750 respectively.
10. Is the market size provided in terms of value or volume?
The market size is provided in terms of value, measured in billion and volume, measured in K Unit.
11. Are there any specific market keywords associated with the report?
Yes, the market keyword associated with the report is "Arthritis Therapeutics Industry," which aids in identifying and referencing the specific market segment covered.
12. How do I determine which pricing option suits my needs best?
The pricing options vary based on user requirements and access needs. Individual users may opt for single-user licenses, while businesses requiring broader access may choose multi-user or enterprise licenses for cost-effective access to the report.
13. Are there any additional resources or data provided in the Arthritis Therapeutics Industry report?
While the report offers comprehensive insights, it's advisable to review the specific contents or supplementary materials provided to ascertain if additional resources or data are available.
14. How can I stay updated on further developments or reports in the Arthritis Therapeutics Industry?
To stay informed about further developments, trends, and reports in the Arthritis Therapeutics Industry, consider subscribing to industry newsletters, following relevant companies and organizations, or regularly checking reputable industry news sources and publications.
Methodology
Step 1 - Identification of Relevant Samples Size from Population Database
Step 2 - Approaches for Defining Global Market Size (Value, Volume* & Price*)
Note*: In applicable scenarios
Step 3 - Data Sources
Primary Research
- Web Analytics
- Survey Reports
- Research Institute
- Latest Research Reports
- Opinion Leaders
Secondary Research
- Annual Reports
- White Paper
- Latest Press Release
- Industry Association
- Paid Database
- Investor Presentations
Step 4 - Data Triangulation
Involves using different sources of information in order to increase the validity of a study
These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.
Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.
During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence